



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



FHL2 (SLIM3) Blocking Peptide

BACKGROUND

Sphingosine kinase-1 (SK1) is a key enzyme that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). SK1, and its product S1P, regulate numerous and diverse biological functions, including cell growth, differentiation, proliferation, and apoptosis. S1P also plays a central role in cardiac development and ischemic preconditioning. FHL2 (SLIM3) has been identified as a SK1-interacting protein in mammalian cardiomyocytes. FHL2, but not FHL1 or FHL3, interacts with SK1, and FHL2 colocalizes with SK1 in the cytoplasm of these cells. The interaction of FHL2 with SK-1 involves the C-terminal portion of SK1. Overexpression of FHL2 has been found to attenuate the activity and antiapoptotic effects of SK1. Endothelin-1, a potent survival factor in cardiomyocytes, inhibits FHL2-SK1 association and increases SK1 activity. FHL2 is therefore a novel inhibitor of SK1 activity in cardiomyocytes and targeting FHL2 may prevent myocardial apoptosis through activation of SK1.

A transcriptional coactivator, FHL2 is also known to form complexes consisting of Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1), FHL2, and androgen receptors (AR) in prostate cancer cells, perhaps functioning as a molecular adaptor with PELP1 in the progression of prostate cancer.

ORDERING INFORMATION

CATALOG NUMBER

X1852B

SIZE

50 μ g

CUSTOMER STORAGE

Product should be stored at -20°C.
Aliquot to avoid freeze/thaw cycles

FORMULATION

Provided as solution in phosphate buffered saline with 0.08% sodium azide

SHIP CONDITIONS

Ship at ambient temperature, freeze upon arrival

STABILITY

Products are stable for one year from purchase when stored properly

COMMENTS

Blocking peptide for use with FHL2 (SLIM3) antibodies (Cat. Nos. X1857P and X1874P).

INSTRUCTIONS

Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 minutes (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.

Example: 10 μ l or 10 μ g of Exalalpha's rabbit anti-FHL2 (Cat. No. X1857P or X1874P) is added to 10 μ g of blocking peptide for a total volume of 20 μ l. The mixture is allowed to incubate for 20 minutes at 37°C prior to dilution in suitable buffer (for Western blot, etc.).